Physician profile
Raul Vela
NPI 1821181678
$12,252.40
in general payments reported to CMS, 2019-2025
30 companies · $2,498 in 2025
The $2,498 reported for 2025 was more than what 81% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $495 · 2020: $471 · 2021: $582 · 2022: $1,740 · 2023: $2,975 · 2024: $3,491 · 2025: $2,498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,840 · Education: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,839.51 |
| Education | $124.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,220.36 | 2019-2025 | Tremfya |
| Abbvie INC. | $2,070.56 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| E.R. Squibb & Sons, L.L.C. | $992.11 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $766.21 | 2022-2025 | Dupixent, Libtayo |
| Amgen INC. | $711.90 | 2020-2025 | Otezla, Otezla |
| Genzyme Corporation | $703.81 | 2021-2025 | |
| Galderma Laboratories, L.P. | $690.03 | 2019-2025 | Nemluvio, Aklief, Twyneo |
| Lilly USA, LLC | $679.49 | 2020-2025 | Taltz, Olumiant, Ebglyss |
| Ucb, INC. | $479.35 | 2022-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $428.53 | 2022-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $343.10 | 2019-2024 | Siliq, Duobrii, Targretin |
| Novartis Pharmaceuticals Corporation | $322.40 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $294.54 | 2020-2025 | Ilumya, Blu-U, Odomzo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $258.71 | 2022-2025 | Spevigo |
| Dermavant Sciences, INC. | $233.22 | 2022-2024 | Vtama |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $180.48 | 2019-2024 | Erivedge, Actemra |
| Leo Pharma INC. | $178.43 | 2020-2025 | Adbry, Anzupgo |
| Sebela Pharmaceuticals INC. | $171.66 | 2019-2020 | |
| Incyte Corporation | $156.87 | 2022-2025 | Opzelura |
| Biofrontera INC. | $123.97 | 2019-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Arcutis Biotherapeutics, INC. | $62.28 | 2023-2024 | Zoryve |
| Epi Health, LLC | $33.02 | 2021 | |
| Organon LLC | $29.43 | 2025 | Vtama |
| Mayne Pharma Commercial LLC | $21.17 | 2019 | |
| Taro Pharmaceuticals USA, INC. | $20.10 | 2019 | |
| Glenmark Therapeutics INC. | $18.00 | 2019 | |
| Mylan Institutional INC. | $17.56 | 2023 | Hulio |
| Celgene Corporation | $17.17 | 2019 | |
| Nobelpharma America, LLC | $14.45 | 2023 | |
| Sandoz INC. | $13.49 | 2025 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raul Vela listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.